Early real-world experience with intravitreal Faricimab for neovascular AMD: FAN study

• Faricimab (Vabysmo™, Roche, Switzerland) improves structural outcomes in patients with recalcitrant fluid after prior intravitreal injection (IVI) therapy. • Foveal centre point (FCP, µm), central subfield retinal thickness (CSRT, µm) and macular volume (mm 3 ) were decreased after switching to faricimab. • No major complications were observed, intraocular inflammation was noted in one eye, which presented with anterior chamber cells and resolved with topical corticosteroid treatment. This study presents real-world experiences and clinical outcomes of patients who switched to faricimab after prior treatment with other anti-vascular endothelial growth factor medication for patients with neovascular age-related macular degeneration (nAMD) in 2022. We evaluated all consecutive patients that received an intravitreal injection (IVI) with faricimab for nAMD and had complete follow-up visits after at least three IVI. Functional and structural parameters including best-corrected visual acuity (BCVA, logMAR), foveal centre point (FCP, µm), central subfield retinal thickness (CSRT, µm) and macular volume (mm 3 ) were evaluated after three (n=71) and five (n=57) faricimab injections with complete follow-up visits. We included 71 eyes of 63 patients. Mean BCVA at baseline was 0.49 logMAR (0 – 1.6) and did not change significantly after five faricimab injections (p=0.33). Significant reductions were seen for FCP, CSRT and macular volume after the first five consecutive injections when compared to baseline (p<0.0001 respectively). FCP was 388.35 µm (173-924 µm) at baseline and decreased to 279.16 µm (97 – 667) at visit 5. CSRT was 370.68 µm (202 – 1074) and decreased to 307.75 µm (168 – 590) at visit 5. Macular volume was reduced from 2.59 mm 3 (1.83 – 4.90) to 2.31 mm 3 (1.80 – 3.19) at visit 5. Intraocular inflammation was observed in one eye showing anterior chamber cells that resolved with topical corticosteroid treatment. The results of the FAN ( FA ricimab for N eovascular AMD) study indicate that faricimab improves structural outcomes in patients with recalcitrant fluid due to nAMD with no major complications observed.